Viking Therapeutics Prepares to Share Third Quarter Insights

Viking Therapeutics Prepares for Financial Results Announcement
Upcoming Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time
Viking Therapeutics, Inc. (NASDAQ: VKTX), a leading clinical-stage biopharmaceutical company, is gearing up to announce its financial results for the third quarter. The release is set for Wednesday, October 22, and will take place after the market closes.
The company will also conduct a conference call at 4:30 p.m. Eastern Time on the same day to discuss these results and provide updates on its corporate developments. Interested participants can join the call by calling (844) 850-0543 from within the U.S. or (412) 317-5199 if calling from outside the U.S. Additionally, a replay of the call will be available until October 29. To listen online, individuals can visit Viking's website and access the Webcast page.
Innovative Developments in Metabolic and Endocrine Treatments
Viking Therapeutics is committed to advancing novel therapies that address metabolic and endocrine disorders. The company's strategic focus is to create first-in-class or best-in-class therapies aimed at improving patient outcomes.
At the forefront of their research is VK2735, a dual agonist designed to activate both the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This ground-breaking treatment is currently undergoing evaluations in a Phase 3 obesity program, which includes two clinical trials known as VANQUISH-1 and VANQUISH-2. Early findings from previous trials indicated a promising safety profile and beneficial effects.
VK2809: Targeting Lipid and Metabolic Disorders
Another significant component of Viking's pipeline is VK2809, an oral small molecule that selectively targets thyroid hormone receptor beta. This innovative compound aims to address lipid and metabolic disorders. In a Phase 2b study for non-alcoholic steatohepatitis (NASH), VK2809 achieved impressive results, meeting both primary and secondary endpoints. Patients showed notable improvements in liver fat content and LDL-C levels.
Exploring Rare Diseases with VK0214
Beyond metabolic conditions, Viking is also making strides in rare diseases, particularly with the development of VK0214. This oral agent intends to treat X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b study involving patients with the adrenomyeloneuropathy form of X-ALD, VK0214 demonstrated a strong safety profile and significant reductions in plasma levels of very long-chain fatty acids.
The Future of Viking Therapeutics
With a robust portfolio of therapies in various stages of development, Viking Therapeutics is well-positioned to impact the treatment landscape for metabolic and endocrine disorders. The upcoming conference call promises to provide insightful updates about their latest advancements and future directions.
For further information about Viking Therapeutics and their innovative therapies, prospective patients and interested stakeholders can learn more through their official website.
Frequently Asked Questions
What is the date of Viking Therapeutics' financial report?
The financial results will be announced on October 22, after the market closes.
How can I participate in the conference call?
You can dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S.
What are the main programs Viking is developing?
Viking is focused on VK2735 for obesity treatment, VK2809 for lipid disorders, and VK0214 for rare diseases.
Where can I find more information about Viking Therapeutics?
More information can be found on their official website.
What are the key benefits of VK2735?
VK2735 aims to provide improved efficacy and safety for patients with metabolic disorders.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.